In a recent study, NLRP3 inhibitor was used to treat PCM in mice, and it was shown that the NLRP3 inhibitor may treat PCM in mice by boosting the quantity and activity of bone marrow-derived suppressor cells (MDSCs) (164) (Figure 4). Here, NLRP3 is linked to paracoccidioidomycosis.